Wednesday, July 8, 2026

pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO

ALX ONCOLOGY HOLDINGS

ALX ONCOLOGY HOLDINGS clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US HQ
2015 Founded
2 Employees
Public company Type
ALXO · NYSE Ticker
Company details
Status
Public
HQ
4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
Founded
2015
Employees
2
Programs
13
Drugs
16
Patents
0
Intelligence · Clinical Programs

ALX ONCOLOGY HOLDINGS projects

1 ClinicalTrials.gov programs sponsored by ALX ONCOLOGY HOLDINGS.

ALX ONCOLOGY HOLDINGS has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ALX ONCOLOGY HOLDINGS have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.